Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of CVL-354 in Healthy Participants
NCT05138653Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Oct 2021
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of icalcaprant in major depressive disorder (MDD) and opioid use disorder (OUD) (15 cohorts), sponsored by Cerevel Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events up to 31 days, Clinically Significant Changes in Electrocardiogram Parameters up to 31 days and 4 more. Started Oct 2021; status: completed.
02
Drugs
icalcaprant
03
Conditions
major depressive disorder (MDD)opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05138653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138653.